Abstract
Ring substituted imidazoles are the emerging class of antitubercular agents. CoMFA model for various ring substituted imidazoles is used to elucidate their structure activity relationships. Both the training set and test set compounds were modeled to the established procedures and were aligned. There was a good correlation between the predicted and experimental activities for both the test set and training set compounds by CoMFA model. Structure activity relations have been established based on the obtained contour maps from the 3D-QSAR analysis.
Keywords: Ring substituted imidazoles, Antitubercular activity, CoMFA, 3D-QSAR
Letters in Drug Design & Discovery
Title: 3D-QSAR Study on Ring Substituted Imidazoles for Their Antitubercular Activity
Volume: 7 Issue: 2
Author(s): Gyanendra Kumar Sharma and Devender Pathak
Affiliation:
Keywords: Ring substituted imidazoles, Antitubercular activity, CoMFA, 3D-QSAR
Abstract: Ring substituted imidazoles are the emerging class of antitubercular agents. CoMFA model for various ring substituted imidazoles is used to elucidate their structure activity relationships. Both the training set and test set compounds were modeled to the established procedures and were aligned. There was a good correlation between the predicted and experimental activities for both the test set and training set compounds by CoMFA model. Structure activity relations have been established based on the obtained contour maps from the 3D-QSAR analysis.
Export Options
About this article
Cite this article as:
Sharma Kumar Gyanendra and Pathak Devender, 3D-QSAR Study on Ring Substituted Imidazoles for Their Antitubercular Activity, Letters in Drug Design & Discovery 2010; 7 (2) . https://dx.doi.org/10.2174/157018010790225912
DOI https://dx.doi.org/10.2174/157018010790225912 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Clinical Assessment of Autonomic Function in Fibromyalgia by the Refined and Abbreviated Composite Autonomic Symptom Score (COMPASS 31): A Case-Controlled Study
Reviews on Recent Clinical Trials Subject Index to Volume 4
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Computational Methods for De novo Protein Design and its Applications to the Human Immunodeficiency Virus 1, Purine Nucleoside Phosphorylase, Ubiquitin Specific Protease 7, and Histone Demethylases
Current Drug Targets Adenosine and Inflammation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science Natural Inhibitors against Potential Targets of Cyclooxygenase, Lipoxygenase and Leukotrienes
Combinatorial Chemistry & High Throughput Screening Compositions for Treatment of Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Autoantibodies as Biomarkers for ANCA-Associated Vasculitides
Current Immunology Reviews (Discontinued) Development of Colon Specific Microspheres of Flurbiprofen for Inflammatory Bowel Disease
Current Drug Delivery The Nervous System as a Critical Regulator of Immune Responses Underlying Allergy
Current Pharmaceutical Design Innate Immune System Modulation During Aging: Contributions of Macrophages and Dendritic Cells
Current Immunology Reviews (Discontinued) Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
Current Cancer Drug Targets Nanobiotechnological Approaches Against Multidrug Resistant Bacterial Pathogens: An Update
Current Drug Metabolism Hypersensitivity Pneumonitis
Current Pediatric Reviews Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies Patent Selections
Recent Patents on Biotechnology